A lthough randomized data and current guidelines advocate pretreatment with intravenous thrombolysis (IVT) in all eligible patients with acute ischemic stroke with large-vessel occlusion (LVO) before mechanical thrombectomy (MT), 1 there are observational data questioning the efficacy of systemic thrombolysis in patients with LVO.
were identified by searching MEDLINE and SCOPUS databases for published randomized controlled clinical trials (RCTs) and observational cohort studies on the use of bridging therapy (IVT followed by MT) for patients with acute ischemic stroke with LVO. Additional details (including the complete search algorithm) for the database search are available in the online-only Data Supplement.
SR at the beginning of MT was defined as modified thrombolysis in cerebral infarction grades of IIb/III on the angiography before MT procedure (second angiographic run) or significant clinical improvement (considered suggestive of SR) amending the need for subsequent MT procedure after tPA bolus. 5 We calculated the point prevalence in all included cohorts by dividing the number of events (SR with IVT pretreatment) by the total number of patients scheduled to receive bridging therapy. Publication bias was evaluated graphically using a funnel plot and with the Egger statistical test for funnel plot asymmetry. After the overall analysis, we performed a post hoc sensitivity analysis after excluding studies not clearly describing the timing of initial vascular imaging in relation to IVT onset. We also conducted additional subgroup analyses according to study type (RCT versus observational study) and the inclusion per protocol of patients with tandem (intracranial/extracranial) occlusions. Finally, we performed meta-regression analyses according to the onset-to-bolus time, bolusto-groin puncture time, and baseline demographic characteristics (admission National Institutes of Health Stroke Scale score, age, and male sex) reported in included studies. Further details on the statistical analysis are available in the online-only Data Supplement.
Results
The flow chart on study selection procedure and the list of excluded studies are available in the online-only Data Supplement ( Figure I in the online-only Data Supplement; Table  I in the online-only Data Supplement). Patient characteristics from eligible cohorts (7 RCTs and 6 observational studies) comprising a total of 1561 patients (median admission National Institutes of Health Stroke Scale, 17) are briefly summarized in the Table (online-only Data Supplement) .
The pooled prevalence of SR was 11% (95% confidence interval [CI], 7%-16%) in the overall analysis of all included studies (online-only Data Supplement) and 12% (95% CI, 8%-17%) in the post hoc sensitivity analysis of eligible studies (n=11) clearly reporting timing of initial vascular imaging in relation to IVT administration ( Figure II in the online-only Data Supplement). In subgroup analysis according to study type, no difference was found among cohorts derived from RCTs 11% (95% CI, 6%-18%) and observational studies 11% (95% CI, 5%-19%). Significant heterogeneity was identified in both the overall analysis, sensitivity analysis, and among subgroups (I 2 >80%; P for Cochran Q, <0.001; Figures II and III in the online-only Data Supplement). The presence of considerable heterogeneity among studies was also evident in the asymmetrical appearance of funnel plot ( Figure IV in the online-only Data Supplement; P for Egger test, 0.041). Studies reporting the exclusion of patients with LVO with tandem occlusions had higher rates of SR (17%; 95% CI, 11%-23%) compared with the rest (7%; 95% CI, 4%-11%; P=0.003; Figure) . Moreover, the detected heterogeneity was the lowest (I 
Discussion
Our meta-analysis showed that 1 in 10 patients with LVO pretreated with IVT achieve SR before MT onset averting additional endovascular procedures. We also documented that part of the heterogeneity across included studies could be explained by the presence of tandem occlusions, which were the least responsive to IVT pretreatment. Finally, the effect of IVT on SR was not modified by onset-to-bolus time, bolusto-groin puncture time, baseline stroke severity, age, or sex. The reported percentage of SR in our meta-analysis (11%; 95% CI, 7%-16%) is significantly lower from the pooled percentage of complete reperfusion reported in a recent metaanalysis of all available patient cohorts treated solely with IVT (20%; 95% CI, 15%-26%). 6 This difference could be attributed to potential underreporting of the incidence of tPA-induced SR because of the design of certain RCTs excluding drip and ship patients with early reperfusion after IVT pretreatment from enrolment in the trials. Moreover, patient selection in these trials was based on vascular imaging that was predominantly conducted after the beginning of tPA infusion, thus potentially missing additional patients with early reperfusion. Our results are complimentary to a recent meta-analysis reporting that IVT pretreatment before MT is associated with higher SR rates (mTICI 2b-3) after MT and a higher likelihood of SR with fewer passes compared with direct MT. 8 This beneficial effect of IVT pretreatment on SR translated into better 3-month functional outcomes with bridging therapy (IVT and MT) compared with direct MT. 8 These findings combined with the observations of our meta-analysis further highlight that pretreatment with IVT may avert the need for additional endovascular procedures (reducing costs and preventing potential complications) in a non-negligible portion of patients with LVO, 2 which could be of paramount importance in patients with LVO with unfavorable vessel anatomy (tortuosity, type III aortic arch) complicating endovascular access to intracranial arterial clots. Finally, the beneficial effect of tPA-induced SR in LVO before MT may be further accentuated in the settings of mobile stroke units given the greater potential for ultraearly treatment within the golden hour (≤60 minutes from symptom onset).
Our findings also indicate that patients with tandem occlusions have the lowest likelihood to achieve SR after systemic thrombolysis and may benefit the most from direct transfer to comprehensive stroke centers for prompt initiation of MT. Clot burden is the highest among patients with tandem occlusions, and this may account for their poor response to IVT. 9 Previous studies evaluating patients with acute ischemic stroke treated with IVT have shown that tandem occlusions are associated with the lowest rates of complete recanalization and 3-month favorable functional outcome. 10, 11 Certain limitations of the present meta-analysis need to be acknowledged, including the moderate sample size and the significant heterogeneity across studies (I 2 >50%) in overall and subgroup analyses. The per-protocol exclusion of patients with SR occurring before MT in many protocols could have been partially responsible for the observed heterogeneity that we detected across included studies but also might have biased the results of the present meta-analysis toward an underestimation of SR. In an effort to account for this possible underestimation of SR, we reviewed the methods on patient selection and imaging procedures of included studies and performed a post hoc sensitivity analysis after excluding those protocols not clearly describing the timing of initial vascular imaging in relation to IVT onset ( Figure II in the online-only Data Supplement). Another major limitation of the present report and possible source of bias, which could further explain part of the documented heterogeneity across included studies, is the inclusion of patients who were reported to have significant clinical improvement after IVT without angiographic confirmation of SR. Third, we were able to assess in univariable meta-regression analyses the potential association of SR after IVT only with age, sex, onset-to-bolus time, bolus-to-groin puncture time, and baseline stroke severity because other baseline characteristics were unavailable in the majority of included studies. Moreover, it should be highlighted that because the aforementioned meta-regression analyses were conducted at the study level, and not at the patient level, their results should be interpreted with caution. Additionally, it should be noted that no subgroup analysis according to the site of occlusion could be performed because of unavailable data. This analysis could be of major importance because response to IVT is known to be influenced by the site of occlusion, 9 whereas the association of tandem occlusions with lower SR rates should ideally have been adjusted for the site of intracranial occlusion. Finally, the potential publication bias could not be reliably assessed because of the substantial heterogeneity across trials.
In conclusion, pretreatment with systemic thrombolysis in patients with LVO eligible for MT results in SR in 1 of 10 cases, negating the need to pursue further endovascular procedures. This beneficial effect of bridging therapy should be further evaluated in the prehospital settings of mobile stroke units that are associated with the swiftest possible tPA delivery in patients with acute ischemic stroke.
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